There has been increased interest in the prophylactic and therapeutic use of high-flow nasal oxygen in patients with, or at risk of, non-hypercapnic respiratory failure. There are no randomised trials examining the efficacy of high-flow nasal oxygen in high-risk cardiac surgical patients. We sought to determine whether routine administration of high-flow nasal oxygen, compared with standard oxygen therapy, leads to reduced hospital length of stay after cardiac surgery in patients with pre-existing respiratory disease at high risk for postoperative pulmonary complications. Adult patients with pre-existing respiratory disease undergoing elective cardiac surgery were randomly allocated to receive high-flow nasal oxygen (n = 51) or standard oxygen therapy (n = 49). The primary outcome was hospital length of stay and all analyses were carried out on an intention-to-treat basis. Median (IQR [range]) hospital length of stay was 7 (6-9 [4-30]) days in the high-flow nasal oxygen group and 9 (7-16 [4-120]) days in the standard oxygen group (p=0.012). Geometric mean hospital length of stay was 29% lower in the high-flow nasal group (95%CI 11-44%, p = 0.004). High-flow nasal oxygen was also associated with fewer intensive care unit re-admissions (1/49 vs. 7/45; p = 0.026). When compared with standard care, prophylactic postoperative high-flow nasal oxygen reduced hospital length of stay and intensive care unit re-admission. This is the first randomised controlled trial examining the effect of prophylactic high-flow nasal oxygen use on patientcentred outcomes in cardiac surgical patients at high risk for postoperative respiratory complications.
Introduction
Patients undergoing cardiac surgery are at significant risk of postoperative pulmonary complications, and these complications may increase morbidity and mortality and lead to prolonged intensive care unit (ICU) and hospital length of stay (LOS) [1] . The reported incidence of postoperative pulmonary complications following cardiac surgery ranges from 8% to 79% [2] . Postoperative pulmonary complications manifest early as hypoxaemia, later pneumonia, and in rare cases also as acute respiratory distress syndrome [3] . The incidence of postoperative pulmonary complications is increased in patients with intrinsic respiratory disease, asthma, chronic obstructive pulmonary disease (COPD) and heavy smokers [4] . These patients often stay longer in the ICU after surgery due to lower respiratory tract infections, impaired ventilation and the need for prolonged ventilatory support. They are also more likely to require re-admission to ICU for unplanned continuous positive airways pressure (CPAP), non-invasive or invasive mechanical ventilation. Therefore, hospital stay is prolonged compared with low-risk patients after cardiac surgery [5] [6] [7] . A contributing mechanism of postoperative pulmonary complications is atelectasis, which has been shown to affect up to 90% of patients undergoing cardiac surgery. Atelectasis has been shown to be resistant to simple techniques such as patient positioning and incentive spirometry [8] . Lung recruitment manoeuvres and positive airways pressure may reduce atelectasis development, but this effect is lost after tracheal extubation [9] .
Prophylactic nasal CPAP reduces postoperative pulmonary complications after cardiac surgery [10] .
However, CPAP is costly and requires more intensive involvement by hospital staff. In many hospitals, its use requires admission to at least a high dependency area or even ICU, thus further increasing costs. Apart from the expense and extra healthcare provision costs, common potential side-effects from CPAP include mask discomfort, skin abrasions, inability to communicate effectively, inability to eat or drink while the device is in use, inability to mobilise and irritation from device noise [11, 12] .
High-flow nasal oxygen therapy delivers warmed humidified oxygen and low level, flow-dependent positive airways pressure, and may be better tolerated than CPAP or non-invasive ventilation; moreover, high-flow nasal oxygen enhances washout of nasopharyngeal dead space, thus improving oxygenation [13] [14] [15] [16] . It has been shown that high-flow nasal oxygen is both safe and noninferior to conventional CPAP in providing prophylactic support to very preterm neonates after extubation while the incidence of nasal trauma was significantly lower than in the CPAP group [17] . No study has assessed the effect of prophylactic use of high-flow nasal oxygen on hospital stay in adult cardiac surgical patients with significant risk factors for postoperative pulmonary complications. We therefore, decided to study high-risk patients with preexisting lung disease (COPD, asthma, recent lower respiratory tract infection), heavy smokers or morbidly obese patients (body mass index (BMI) ≥ 35 kg.m
À2
), who were expected to stay longer in ICU and hospital due to increased respiratory complications. We tested the hypothesis that routine administration of high-flow nasal oxygen leads to reduced hospital length of stay after cardiac surgery compared with standard oxygen therapy.
Methods

Following national research ethics service (East Midlands
Research Ethics Committee UK) and local Research and Development approval, written informed consent was obtained from all patients. Patients scheduled for elective cardiac surgery (coronary artery bypass grafting (CABG), valve surgery or both) were screened for eligibility.
Patients were included in the trial if they were aged > 18 years, had one or more patient-related risk factors for postoperative pulmonary complications (COPD, asthma, lower respiratory tract infection in preceding four weeks, BMI ≥ 35 kg.m À2 , current (within last six weeks) heavy smokers (> 10 pack years)) and were capable of performing a 6-minute walk test (6MWT). Only patients with a formal COPD or asthma diagnosis (as defined by British Thoracic Society and National Institute for Health and Care Excellence) on inhaled therapy were enrolled [18, 19] . Lower respiratory tract infection was defined according to National Institute for Health and Care Excellence as an acute illness, usually with cough as the main symptom, and with at least one other lower respiratory tract symptom (such as fever, sputum production, breathlessness, wheeze or chest discomfort/pain) and no alternative explanation [20] .
According to the trial protocol, patients in whom high-flow nasal oxygen was contraindicated (presence of a nasal septal defect), those who needed CPAP pre-operatively or those who did not meet tracheal extubation criteria by 10.00 the day after surgery (as they did not follow the local protocolised peri-operative care pathway), were not studied. Randomisation was performed using a computer-generated assignment sequence and a centralised online system before the induction of anaesthesia while the patients were in the operating theatre. Participating patients were randomly allocated in a 1:1 ratio (block randomisation procedure with randomly selected block sizes keeping the investiga- analgesia for all patients, unless they had a specific contraindication (e.g. known drug allergy).
Following tracheal extubation, patients received either high-flow nasal oxygen or standard oxygen therapy, that is, low-flow oxygen via nasal prongs or a soft facemask, according to the randomisation performed before surgery.
The high-flow nasal oxygen was set up and connected to the patients by the ICU nurses who had been trained before the start of the study. The fraction of inspired oxygen (F I O 2 ) delivered was titrated to that which resulted in a pulse oximeter saturation of at least 95% (93% for those at risk of hypercapnic respiratory failure, such as confirmed COPD patients and morbidly obese patients)
according to the British Thoracic Society guidelines for oxygen use in adult patients [22] . The F I O 2 was actively reduced to the minimum level which achieved this goal.
Gas The primary outcome of the study was hospital stay. 
Results
One hundred patients were enrolled in the study, 51 patients were allocated to receive high-flow nasal oxygen and 49 to receive standard oxygen therapy. Of these, six patients were not included in the final analysis due to protocol violation (two patients in each group
were not extubated by 10:00 on the morning after surgery), surgery being cancelled (one patient in the standard oxygen group) and withdrawal of consent (one patient in the standard oxygen group) (Fig. 1 ).
All other randomly allocated patients were included in the intention-to-treat analysis. Baseline and clinical characteristics (including logistic EuroScore) are shown in Table 1 . Study end-points are reported in Table 2 . (Table 3 ). The recovery profiles for each PQRS domain are summarised in Table 4 . The differences in patient-reported outcomes between the two groups were not statistically significant.
Discussion
In this study, we randomly assigned patients undergoing cardiac surgery and at high risk for postoperative between-group differences in other secondary outcomes.
Airflow limitation strongly predicts increased hospital stay and in-hospital mortality after cardiac surgery [24] .
The beneficial effect of high-flow nasal oxygen after cardiac surgery and reduction in hospital stay in our study cohort could potentially be explained by the following mechanisms: washout of nasopharyngeal dead space; reduced work of breathing; improved respiratory mechanics; and generation of low-level PEEP [25] [26] [27] .
The warmed and humidified oxygen facilitates optimum function of the airway mucosa and mucociliary clearance, and inhibits bronchomotor response, thus preventing bronchospasm and increases in airway resistance [28, 29] . It has been shown that high-flow nasal oxygen reduces dead space ventilation in a flow-and time-dependent manner, leading to a reduction in [18, 19] . c LRTI was defined according to National Institute for Health and Care Excellence as an acute illness, usually with cough as the main symptom, and with at least one other lower respiratory tract symptom (such as fever, sputum production, breathlessness, wheeze or chest discomfort or pain) and no alternative explanation [20] . d Logistic EUROSCORE is a risk model which allows prediction of mortality after cardiac surgery. It includes 17 factors (patient-, cardiac-and operation related) and uses logistic regression to calculate mortality risk.
rebreathing, more effective alveolar ventilation and decreased work of breathing [26] . In the non-cardiac surgery setting, high-flow nasal oxygen is increasingly being used as a first-line therapy in acute respiratory failure. This strategy is supported by data from well-designed and adequately powered trials
showing that high-flow nasal oxygen application reduces tracheal re-intubation rate in low-risk patients [30] when compared with conventional oxygen therapy, confers survival benefit [31] and results in a lower tracheal re-intubation rate [32] in patients with, or at risk of, non-hypercapnic hypoxaemic respiratory failure.
However, a recent systematic review of 11 randomised were the main limitations of these studies. Furthermore, reporting 'non-validated' surrogate primary outcomes is more likely to result in overestimation of treatment effect and uncertainty in predicting treatment benefit [36] .
We selected hospital stay as the primary outcome because it is more relevant to patients and healthcare providers than physiological parameters such as oxygenation or haemodynamic data. Length of stay integrates postoperative pulmonary and extra-pulmonary complications, and speed of postoperative recovery. It is, therefore, a non-mortality patient-centred outcome which reflects quality and value-based healthcare delivery [37, 38] .
A recent meta-analysis which included the aforementioned two randomised trials only, examined the efficacy and safety of high-flow nasal oxygen after cardiac surgery compared with conventional oxygen therapy and found that post-extubation application of high-flow nasal oxygen was associated with a significant reduction in escalation of respiratory support (RR, 0.61; 95%CI, 0.46-0.82; z = 3.32, p < 0.001) [39] . However, due to the small number of studies analysed, the methods utilised to detect publication bias were underpowered. In addition, the definitions, strategies and criteria for escalation of respiratory support in the studies included in the meta-analysis were non-specific, making the validity of the results questionable. The differences in escalation of respiratory support (unplanned CPAP, non-invasive or invasive ventilation) between the high-flow nasal oxygen group and the standard oxygen group in our study cohort were non-significant.
In a large (n = 830) 'non-inferiority' multi-centre randomised trial, high-flow nasal oxygen was compared with BiPAP in patients with, or at risk of, respiratory failure after cardiothoracic surgery [40] . The primary outcome in this study was treatment failure, which was defined as a composite of tracheal re-intubation, switch to the other study therapy or early discontinuation of the assigned therapy, and the authors concluded that highflow nasal oxygen was not inferior to BiPAP. The control group in this study does not necessarily represent the standard of care or best practice because there are no robust data indicating that BiPAP improves outcomes in the cardiac surgery setting. In addition, by using a composite primary outcome, the effect may be small for important individual components (e.g. tracheal re-intubation rate) and large for less important clinical components (e.g. crossover to another treatment group), limiting the generalisability of the results [41] . A recent post-hoc analysis in the subset of obese (BMI > 30 kg.m Our trial has several limitations. Firstly, there is potential bias due to a lack of blinding of the patients and healthcare providers in the immediate postoperative period due to the obvious differences between the study interventions. Secondly, our study was underpowered for some of the secondary outcomes, for example, 6MWT
and patient-reported outcomes, and the composite of postoperative complications. Although we did not discern significant between-group differences in patientreported outcomes, we highlight the importance of reporting recovery profiles as they reflect value-based care and provide potentially useful information in order to adequately power future studies. Thirdly, the single centre status of our study and potentially associated large intervention effect may not be directly transferable to other settings [43] .
In conclusion, when compared with standard care, prophylactic postoperative use of high-flow nasal oxygen in cardiac surgical patients at high risk for postoperative respiratory complications reduced hospital length of stay and re-admissions to ICU. This has implications for reduced healthcare costs and potentially morbidity. We recommend routine use of high-flow nasal oxygen after tracheal extubation in this cohort of patients and further testing of our hypothesis in large multi-centre randomised trials.
